

For Public Release
NZX Limited
Wellington

31 October 2023

Cannasouth to Sell Verified Dried Cannabis Flower Products

Following the recent verification of its two CBD Oral Solutions products announced last week Cannasouth Limited (**NZX: CBD**) is pleased to announce the successful assessment of its first three dried cannabis flower products by the Medicinal Cannabis Agency.

The verification provides the market with the first New Zealand dried cannabis flower products that are 100% grown, processed, and packaged locally, for use by local patients. It sets the benchmark in New Zealand's rigorous regulatory environment and its current reliance on imported products (including products which are exported for processing and re-imported).

Cannasouth successfully merged with Eqalis Group on June 1, 2023, providing Cannasouth with integrated operational capacities, creating the largest NZX listed medicinal cannabis company, and delivering end-to-end GMP manufacturing capabilities.

Cannasouth CEO Mark Lucas says "In countries like New Zealand, where medical cannabis is now legal, the price difference between the current green (legal) and black market is enormous. Our goal is to bridge this gap by offering high-quality, competitively priced products, thereby shifting the paradigm from the black (illegal) to the green users market. This is a win-win situation, providing better patient access to safe medicinal cannabis while creating a robust, legitimate market that drives economic value and shareholder returns."

Looking ahead, Cannasouth is leveraging its strengthened position, especially as it rolls out its pipeline of new products to expand market opportunities in Australasia, drive down costs for patients, and deliver value to its shareholders and the community at large. The company's global ambitions are underpinned by disruptive processing and drug delivery technologies, which will provide the next wave of revenue, building on near-term sales.

A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: <https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard>

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqlis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>